Mick Whitley: To ask the Secretary of State for Health and Social Care, for what reasons his Department has not made Evusheld available to immunocompromised people; and if he will make a statement.
Catherine West: To ask the Secretary of State for Health and Social Care, with reference to the Government's decision not to procure Evusheld, what steps she will take to help ensure that immunocompromised people are protected from covid-19 this winter.
Andrew Gwynne: To ask the Secretary of State for Health and Social Care, whether it remains her Department's policy to not procure Evusheld.
Catherine West: To ask the Secretary of State for Health and Social Care, for what reason the Government decided not to procure Evusheld.
Henry Smith: To ask the Secretary of State for Health and Social Care, whether his Department plans to extend the availability of Evusheld as a covid-19 prophylactic treatment through clinical trials for immunocompromised individuals.
Barbara Keeley: To ask the Secretary of State for Health and Social Care, whether the Government took account of the recent Israeli study on the efficacy of Evusheld, published on 29 July 2022, as part of its decision on whether to procure Evusheld.
Vicky Foxcroft: ...of State for Health and Social Care, if he will provide the names of the experts who were consulted on the Government’s decision, announced on 12 August 2022, not to purchase any doses of Evusheld at this time.
Daisy Cooper: To ask the Secretary of State for Health and Social Care, if his Department will publish all evidence provided by immunologists to inform the decision not to procure Evusheld.
Catherine West: To ask the Secretary of State for Health and Social Care, when he will make a decision on the availability of Evusheld covid-19 vaccine for immunocompromised people.
Vicky Foxcroft: To ask the Secretary of State for Health and Social Care, whether he plans to expand the availability of Evusheld as a prophylactic through clinical trials.
Virginia Crosbie: To ask the Secretary of State for Health and Social Care, what assessment the UK Health Security Agency of the effectiveness of the drug Evusheld against the Omicron variant of covid-19; and if she will make that treatment available on the NHS to people who are immunocompromised.
Kevan Jones: To ask the Secretary of State for Health and Social Care, when he expects NICE's review of Evusheld to be concluded.
Theresa Villiers: To ask the Secretary of State for Health and Social Care, what discussions he has had with the NHS on making the drug Evusheld available for treatment of people with compromised immune systems who are at risk of serious harm from covid-19.
Lord Mendelsohn: ...what plans they have (1) to meet with charities working with the clinically extremely vulnerable to COVID-19, and (2) to set out their strategy for protecting the clinically extremely vulnerable if Evusheld is not procured and made available; and what assessment they have made of how effectively this strategy will protect the clinically extremely vulnerable in the absence of Evusheld...
Andrew Gwynne: To ask the Secretary of State for Health and Social Care, if he will take steps to ensure that the continued consultations around the rollout of Evusheld do not impede his Department’s ability to procure that antiviral drug.
Ben Lake: To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 14 June 2022 to Question 15354 on Evusheld, whether his Department has received advice from clinicians on the most appropriate option for the use of Evusheld.
Andrew Gwynne: To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 12 July 2022 to Question 31781 on Evusheld, when he plans to conclude the consultation with clinicians on the rollout of Evusheld.
Fabian Hamilton: To ask the Secretary of State for Health and Social Care, if he will make Evusheld available to immunocompromised patients on the NHS.
Andrew Gwynne: To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 12 July 2022 to Question 31781 on Evusheld, whether patient groups representing people who are (a) clinically vulnerable, (b) clinically extremely vulnerable and (c) immunosuppressed have been consulted on the rollout of Evusheld.
Dan Jarvis: To ask the Secretary of State for Health and Social Care, what plans his Department has to procure Evusheld for the purposes of prescribing to clinically vulnerable patients for protection against covid-19.